ASHP Guidelines on Pharmacy Services in Solid Organ Transplantation

Solid organ transplantation is a lifesaving procedure for thousands of people with irreversible end organ diseases. A multidisciplinary approach with inclusion of a pharmacist in the care of transplant recipients is highly desired and may necessitate the addition of transplant pharmacy resources to existing teams to meet these growing needs. By understanding and leveraging the current landscape of leadership priorities,

Section: Regulatory Compliancementioning

confidence: 99%

“…Similarly, the ASHP guidelines for pharmacy services in solid organ transplantation can be a useful resource to compare current vs described best practices. 2…”

Section: Cms Requirement Metricsmentioning

confidence: 99%

Considerations and approaches to expansion of solid organ transplant pharmacist services

Doligalski

Anger

Dick

et al. 2021

“…Development of standards of practice in the U.S. can be done rapidly through modification and integration of successful Canadian models, 62 core competencies of clinical pharmacists from the American College of Clinical Pharmacy (ACCP), 64 and standards of practice examples from solid organ transplantation 65 . Qualifications of pharmacists should include eligibility to perform CMM (accredited residency training or equivalent postlicensure clinical experience and board certification) and training in nephrology, including postgraduate and certificate programs.…”

Section: Next Stepsmentioning

confidence: 99%

Nephrology practice and research network opinion paper: Pharmacists' perspectives on the Advancing American Kidney Health initiative

Meaney

Manley²,

Pai

et al. 2020

Patients with chronic kidney disease (CKD) are at high risk for clinically significant medication therapy problems (MTPs) due primarily to the complex pharmacotherapy prescribed by numerous providers, and the significant changes in pharmacokinetic and pharmacodynamic properties of many medications due to their kidney disease. While MTPs are well recognized, pharmacists are not routinely involved in the health care teams that provide care for patients with CKD. The Advancing American Kidney Health initiative was announced in July 2019 and is poised to shift models of care in nephrology toward value‐based payment. This represents an opportunity for pharmacists to integrate into teams to improve quality of care and outcomes for patients with CKD. Pharmacists should engage in medication reconciliation, transitions of care, and medication‐focused kidney disease education programs within a comprehensive medication management (CMM) framework to optimize pharmacotherapy outcomes. To implement these services, pharmacists need to utilize certified pharmacy technicians, telehealth, interprofessional skills, and other tools in innovative ways. Current models of successful practice from Canada can serve as a template for United States‐based nephrology pharmacy practice. In this opinion paper, we characterize the current state of nephrology practice and identify significant opportunities for advancement. We propose metrics to evaluate pharmacy services and a framework for key stakeholder engagement which will be critical to advance the profession of pharmacy within nephrology. The Advancing American Kidney Health initiative offers a distinct opportunity to demonstrate the value of CMM provided by pharmacists in the nephrology arena to optimize patient care.

“…The American Society of Health-System Pharmacists (ASHP) recently published guidance regarding specifics on pharmacotherapy services which should be provided to all transplant patients. 5 Lastly, transplant pharmacist board certification (BCTXP), provided by the Board of Pharmaceutical Specialties, has been approved after publication and review of an in-depth role delineation study. 6 As of August 2018, there were 42 post-graduate year two (PGY2) solid organ transplant (SOT) pharmacy residency programs accredited or undergoing the accreditation process through the ASHP, which represents significant growth compared with the two ASHP-accredited PGY2 SOT pharmacy residency programs in 2007.…”

Section: Introductionmentioning

confidence: 99%

“…However, current regulations include no detail on the type or duration of required transplant experience or in what circumstances they provide comprehensive pharmaceutical care (eg, inpatient, outpatient, for how long after transplant). The American Society of Health‐System Pharmacists (ASHP) recently published guidance regarding specifics on pharmacotherapy services which should be provided to all transplant patients 5 . Lastly, transplant pharmacist board certification (BCTXP), provided by the Board of Pharmaceutical Specialties, has been approved after publication and review of an in‐depth role delineation study 6…”

Section: Introductionmentioning

confidence: 99%

Survey‐based assessment of shifting trends in first solid organ transplant pharmacist jobs

Horwedel¹,

Crowther

Jenkins

et al. 2021

Introduction Tremendous growth in post‐graduate year 2 (PGY2) and fellowship training opportunities in Solid Organ Transplantation has been seen throughout the 2010s, and efforts to assess the impact and ongoing needs for training are needed. Objectives The American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network (ACCP IMTR PRN) conducted a survey of its membership in 2018 to assess the initial positions held by its members within the solid organ transplant space in order to evaluate the job market to optimize trainee competitiveness upon graduation. Methods The ACCP IMTR PRN Workforce Committee developed a survey through an iterative process assessing pharmacists' first job related to solid organ transplant. Survey content was divided into questions regarding formal training, first job structure, and first job responsibilities. The final survey included 59 questions utilizing branch logic questioning, thus respondents did not answer questions that were not relevant based upon previous responses. Results There were 206 analyzable responses representing pharmacists starting between 1986 and 2017, with the majority starting between 2013 and 2017. Before 2013, 52% of respondents had completed a PGY2 residency specializing in solid organ transplant, compared with 68% of respondents between 2013 and 2017. When comparing responses with first jobs between 2013 and 2017 as compared with the earlier era, more jobs were purely inpatient (32 vs 24%) more were purely dedicated to the transplant population (87 vs 79%), and more had medication order entry as a job responsibility (65 vs 47%). Conclusions The results of this survey should be used to help guide the development of post‐graduate specialty training in solid organ transplant to prepare residency and fellowship graduates for first job responsibilities.